286 related articles for article (PubMed ID: 19402129)
1. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the met receptor in mesothelioma.
Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
[TBL] [Abstract][Full Text] [Related]
4. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.
Ferracini R; Di Renzo MF; Scotlandi K; Baldini N; Olivero M; Lollini P; Cremona O; Campanacci M; Comoglio PM
Oncogene; 1995 Feb; 10(4):739-49. PubMed ID: 7862451
[TBL] [Abstract][Full Text] [Related]
5. MET oncogene aberrant expression in canine osteosarcoma.
Ferracini R; Angelini P; Cagliero E; Linari A; Martano M; Wunder J; Buracco P
J Orthop Res; 2000 Mar; 18(2):253-6. PubMed ID: 10815826
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors.
Flint AF; U'Ren L; Legare ME; Withrow SJ; Dernell W; Hanneman WH
Vet Pathol; 2004 May; 41(3):291-6. PubMed ID: 15133183
[TBL] [Abstract][Full Text] [Related]
7. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
8. Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Khanna C; Khan J; Nguyen P; Prehn J; Caylor J; Yeung C; Trepel J; Meltzer P; Helman L
Cancer Res; 2001 May; 61(9):3750-9. PubMed ID: 11325848
[TBL] [Abstract][Full Text] [Related]
9. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.
Coltella N; Manara MC; Cerisano V; Trusolino L; Di Renzo MF; Scotlandi K; Ferracini R
FASEB J; 2003 Jun; 17(9):1162-4. PubMed ID: 12709413
[TBL] [Abstract][Full Text] [Related]
10. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Berthou S; Aebersold DM; Schmidt LS; Stroka D; Heigl C; Streit B; Stalder D; Gruber G; Liang C; Howlett AR; Candinas D; Greiner RH; Lipson KE; Zimmer Y
Oncogene; 2004 Jul; 23(31):5387-93. PubMed ID: 15064724
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
12. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.
Liao AT; McCleese J; Kamerling S; Christensen J; London CA
Vet Comp Oncol; 2007 Sep; 5(3):177-96. PubMed ID: 19754789
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling.
Cantiani L; Manara MC; Zucchini C; De Sanctis P; Zuntini M; Valvassori L; Serra M; Olivero M; Di Renzo MF; Colombo MP; Picci P; Scotlandi K
Cancer Res; 2007 Aug; 67(16):7675-85. PubMed ID: 17699771
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-11 receptor alpha is expressed on canine osteosarcoma.
Sottnik JL; Thamm DH
Vet Comp Oncol; 2010 Jun; 8(2):96-102. PubMed ID: 20579322
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
17. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
18. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
19. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
